{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:05:27Z","timestamp":1793106327416,"version":"4.5.0"},"reference-count":165,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.lfs.2022.121048","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T02:23:47Z","timestamp":1665109427000},"page":"121048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and\/or anti-SARS-CoV-2"],"prefix":"10.1016","volume":"309","author":[{"given":"Samar A.","family":"Antar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Al-Karmalawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2022.121048_bb0005","series-title":"Pirfenidone is a Renal Protective Drug: Mechanisms, Signalling Pathways, and Preclinical Evidence","first-page":"174503","volume":"911","author":"Bai","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/08941939.2016.1215578","article-title":"Effect of pirfenidone on vascular proliferation, inflammation and fibrosis in an abdominal adhesion rat model","volume":"30","author":"Hasdemir","year":"2017","journal-title":"J. Investig. Surg."},{"key":"10.1016\/j.lfs.2022.121048_bb0015","series-title":"Medicine M. PPAR\u03b3\/NF-\u03baB and TGF-\u03b21\/Smad Pathway are Involved in the Anti-fibrotic Effects of Levo-tetrahydropalmatine on Liver Fibrosis","first-page":"1645","volume":"25","author":"Yu","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0020","series-title":"A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases","first-page":"13","author":"Shah","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0025","series-title":"Discovery D. From Dissection of Fibrotic Pathways to Assessment of Drug Interactions to Reduce Cardiac Fibrosis and Heart Failure","first-page":"100036","volume":"2","author":"Garoffolo","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0030","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1167\/iovs.09-4257","article-title":"Antifibrotic effect of pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels","volume":"51","author":"Kim","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.lfs.2022.121048_bb0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1183\/09059180.00001111","article-title":"Antifibrotic activities of pirfenidone in animal models","volume":"20","author":"Schaefer","year":"2011","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.lfs.2022.121048_bb0040","series-title":"Renoprotective Mechanisms of Pirfenidone in Hypertension-induced Renal Injury: Through Anti-fibrotic and Anti-oxidative Stress Pathways","first-page":"309","volume":"34","author":"Ji","year":"2013"},{"key":"10.1016\/j.lfs.2022.121048_bb0045","series-title":"Oxidative Stress Induced by Reactive Oxygen Species (ROS) and NADPH Oxidase 4 (NOX4) in the Pathogenesis of the Fibrotic Process in Systemic Sclerosis: A Promising Therapeutic Target","first-page":"4791","volume":"10","author":"Piera-Velazquez","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0050","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lfs.2022.121048_bb0055","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd3495","article-title":"Pirfenidone","volume":"10","author":"Richeldi","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2022.121048_bb0060","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2019.06.001","article-title":"Patient journey and treatment patterns in adults with IPF based on health care data in Sweden from 2001 to 2015","volume":"155","author":"Sk\u00f6ld","year":"2019","journal-title":"Respir. Med."},{"key":"10.1016\/j.lfs.2022.121048_bb0065","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3181\/00379727-216-44187","article-title":"Pirfenidone attenuates bleomycin-induced changes in pulmonary functions in hamsters","volume":"216","author":"Schelegle","year":"1997","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.lfs.2022.121048_bb0070","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/resp.14044","article-title":"Preoperative use of pirfenidone and reduced risk of postoperative severe respiratory complications in patients with idiopathic pulmonary fibrosis: propensity score-matched analysis using a nationwide database in Japan","volume":"26","author":"Urushiyama","year":"2021","journal-title":"Respirology"},{"key":"10.1016\/j.lfs.2022.121048_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-76271-3","article-title":"Pirfenidone regulates LPS mediated activation of neutrophils","volume":"10","author":"Evani","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2022.121048_bb0080","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3390\/ph13110348","article-title":"Pirfenidone and vitamin D ameliorate cardiac fibrosis induced by doxorubicin in ehrlich ascites carcinoma bearing mice: modulation of monocyte chemoattractant Protein-1 and Jun N-terminal Kinase-1 pathways","volume":"13","author":"Saleh","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.lfs.2022.121048_bb0085","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pupt.2009.03.003","article-title":"Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults","volume":"22","author":"Rubino","year":"2009","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2022.121048_bb0090","series-title":"Discharge May Not be the End of Treatment: Pay Attention to Pulmonary Fibrosis Caused by Severe COVID-19","first-page":"1378","volume":"93","author":"Zhang","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0095","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.saa.2018.06.016","article-title":"Synthesis and photophysical properties of deuteration of pirfenidone","volume":"204","author":"Yin","year":"2018","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.lfs.2022.121048_bb0100","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.2165\/11207710-000000000-00000","article-title":"Pirfenidone","volume":"71","author":"Carter","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.lfs.2022.121048_bb0105","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1021\/acs.jmedchem.9b02073","article-title":"Metabolic activation of pirfenidone mediated by cytochrome p450s and sulfotransferases","volume":"63","author":"Zhou","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2022.121048_bb0110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.fct.2017.12.034","article-title":"Pirfenidone protects against paraquat-induced lung injury and fibrosis in mice by modulation of inflammation, oxidative stress, and gene expression","volume":"112","author":"Pourgholamhossein","year":"2018","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.lfs.2022.121048_bb0115","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3109\/15563650.2012.718783","article-title":"Effect of pirfenidone on pulmonary fibrosis due to paraquat poisoning in rats","volume":"50","author":"Seifirad","year":"2012","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.lfs.2022.121048_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4254\/wjh.v10.i1.1","article-title":"Role of inflammatory response in liver diseases: therapeutic strategies","volume":"10","author":"Del Campo","year":"2018","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.lfs.2022.121048_bb0125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejphar.2008.06.110","article-title":"Potent antioxidant role of pirfenidone in experimental cirrhosis","volume":"595","author":"Salazar-Montes","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2022.121048_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107593","article-title":"Pirfenidone mediates cigarette smoke extract induced inflammation and oxidative stress in vitro and in vivo","volume":"96","author":"Ma","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.lfs.2022.121048_bb0135","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2220\/biomedres.34.309","article-title":"Renoprotective mechanisms of pirfenidone in hypertension-induced renal injury: through anti-fibrotic and anti-oxidative stress pathways","volume":"34","author":"Ji","year":"2013","journal-title":"Biomed. Res."},{"key":"10.1016\/j.lfs.2022.121048_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12890-017-0462-y","article-title":"Exploring efficacy and safety of oral pirfenidone for progressive, non-IPF lung fibrosis (RELIEF)-a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial","volume":"17","author":"Behr","year":"2017","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.lfs.2022.121048_bb0145","article-title":"The effects of pirfenidone on ischaemia\u2013reperfusion injury in testicular torsion-induced rat model","volume":"53","author":"K\u00f6l\u00fck\u00e7\u00fc","year":"2021","journal-title":"Andrologia"},{"key":"10.1016\/j.lfs.2022.121048_bb0150","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3390\/antiox9111064","article-title":"Effects of pirfenidone and nintedanib on markers of systemic oxidative stress and inflammation in patients with idiopathic pulmonary fibrosis: a preliminary report","volume":"9","author":"Fois","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.lfs.2022.121048_bb0155","doi-asserted-by":"crossref","first-page":"6989","DOI":"10.1016\/j.bmc.2011.10.016","article-title":"Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine,-pyrazine and-oxazine dione derivatives as novel dual Nox4\/Nox1 inhibitors","volume":"19","author":"Gaggini","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.lfs.2022.121048_bb0160","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12882-019-1364-4","article-title":"Pirfenidone prevents acute kidney injury in the rat","volume":"20","author":"Lima-Posada","year":"2019","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.lfs.2022.121048_bb0165","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/TP.0b013e3182584879","article-title":"Inhibitory effects of pirfenidone on dendritic cells and lung allograft rejection","volume":"94","author":"Bizargity","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.lfs.2022.121048_bb0170","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/23\/50\/505101","article-title":"Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice","volume":"23","author":"Trivedi","year":"2012","journal-title":"Nanotechnology"},{"key":"10.1016\/j.lfs.2022.121048_bb0175","series-title":"Ballistic Helmets\u2013their Design, Materials, and Performance Against Traumatic Brain Injury","first-page":"313","volume":"101","author":"Kulkarni","year":"2013"},{"key":"10.1016\/j.lfs.2022.121048_bb0180","series-title":"Neuroplasticity in Stroke Recovery. The Role of Microglia in Engaging and Modifying Synapses and Networks","first-page":"1414","volume":"47","author":"Sandvig","year":"2018"},{"key":"10.1016\/j.lfs.2022.121048_bb0185","series-title":"Effects of Pirfenidone on Experimental Head Injury in Rats","first-page":"20","volume":"15","author":"Bozkurt","year":"2022"},{"key":"10.1016\/j.lfs.2022.121048_bb0190","series-title":"Surgical Treatment of Intestinal Stricture in Inflammatory Bowel Disease","first-page":"355","volume":"21","author":"Mohan","year":"2020"},{"key":"10.1016\/j.lfs.2022.121048_bb0195","series-title":"Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease","first-page":"337","volume":"28","author":"Bamias","year":"2022"},{"key":"10.1016\/j.lfs.2022.121048_bb0200","series-title":"A Novel Role of Pirfenidone in Attenuation Acetic Acid Induced Ulcerative Colitis by Modulation of TGF-\u03b21\/JNK1 Pathway","first-page":"108289","volume":"101","author":"Antar","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0205","series-title":"Biology M. Pirfenidone: Molecular Mechanisms and Potential Clinical Applications in Lung Disease","first-page":"413","volume":"62","author":"Ruwanpura","year":"2020"},{"key":"10.1016\/j.lfs.2022.121048_bb0210","series-title":"PD-1 Up-regulation on CD4+ T Cells Promotes Pulmonary Fibrosis Through STAT3-mediated IL-17A and TGF-\u03b21 Production","volume":"10","author":"Celada","year":"2018"},{"key":"10.1016\/j.lfs.2022.121048_bb0215","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.kjms.2017.03.011","article-title":"The effects of pirfenidone on T helper cells in prevention of intraperitoneal adhesions","volume":"33","author":"Ozbilgin","year":"2017","journal-title":"Kaohsiung J. Med. Sci."},{"key":"10.1016\/j.lfs.2022.121048_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-019-1093-z","article-title":"Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-\u03b21","volume":"20","author":"Jin","year":"2019","journal-title":"Respir. Res."},{"key":"10.1016\/j.lfs.2022.121048_bb0225","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/hr.2011.139","article-title":"The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice","volume":"35","author":"Yamazaki","year":"2012","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.lfs.2022.121048_bb0230","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/1060028020964451","article-title":"Systematic review and meta-analysis of pirfenidone, nintedanib, and pamrevlumab for the treatment of idiopathic pulmonary fibrosis","volume":"55","author":"Di Martino","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.lfs.2022.121048_bb0235","series-title":"A Brief Review on Pleiotropic Effects of Pirfenidone-novel and Ongoing Outcomes","first-page":"06","volume":"8","author":"Ravishankar","year":"2019"},{"key":"10.1016\/j.lfs.2022.121048_bb0240","series-title":"Mechanisms of Progressive Fibrosis in Connective Tissue Disease (CTD)-Associated Interstitial Lung Diseases (ILDs)","first-page":"143","volume":"80","author":"Spagnolo","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0245","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ahj.2020.01.009","volume":"222","author":"Udelson","year":"2020","journal-title":"Am. Heart J."},{"key":"10.1016\/j.lfs.2022.121048_bb0250","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2639081","article-title":"Antioxidant activity mediates pirfenidone antifibrotic effects in human pulmonary vascular smooth muscle cells exposed to sera of idiopathic pulmonary fibrosis patients","volume":"2018","author":"Fois","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.lfs.2022.121048_bb0255","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3389\/fonc.2019.01550","article-title":"The multi-modal effect of the anti-fibrotic drug pirfenidone on NSCLC","volume":"9","author":"Marwitz","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2022.121048_bb0260","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/nep.12831","article-title":"Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis","volume":"22","author":"Li","year":"2017","journal-title":"Nephrology"},{"key":"10.1016\/j.lfs.2022.121048_bb0265","first-page":"1","article-title":"Human umbilical cord mesenchymal stem cell conditioned medium attenuates renal fibrosis by reducing inflammation and epithelial-to-mesenchymal transition via the TLR4\/NF-\u03baB signaling pathway in vivo and in vitro","volume":"9","author":"Liu","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.lfs.2022.121048_bb0270","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3389\/fphar.2021.692551","article-title":"Dissecting the role of mesenchymal stem cells in idiopathic pulmonary fibrosis: cause or solution","volume":"12","author":"Samarelli","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2022.121048_bb0275","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/ijms21020524","article-title":"Idiopathic pulmonary fibrosis: pathogenesis and the emerging role of long non-coding RNAs","volume":"21","author":"Hadjicharalambous","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2022.121048_bb0280","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00580-020-03104-0","article-title":"Effects of pirfenidone, vitamin E, and pirfenidone\u2013vitamin E combination in paraquat-induced pulmonary fibrosis","volume":"29","author":"Rasooli","year":"2020","journal-title":"Comp. Clin. Pathol."},{"key":"10.1016\/j.lfs.2022.121048_bb0285","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/TCRM.S81141","article-title":"Role of pirfenidone in the management of pulmonary fibrosis","volume":"13","author":"Meyer","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.lfs.2022.121048_bb0290","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lfs.2022.121048_bb0295","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lfs.2022.121048_bb0300","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2022.121048_bb0305","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2022.121048_bb0310","series-title":"Focusing on Idiopathic Pulmonary Fibrosis","first-page":"80","volume":"7","author":"Chaudhry","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0315","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40268-020-00311-6","article-title":"Cutaneous adverse events in newly approved FDA non-cancer drugs: a systematic review","volume":"20","author":"Macklis","year":"2020","journal-title":"Drugs R&D"},{"issue":"9","key":"10.1016\/j.lfs.2022.121048_bb0320","article-title":"Non-steroid agents for idiopathic pulmonary fibrosis","author":"Spagnolo","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lfs.2022.121048_bb0325","series-title":"Idiopathic Pulmonary Fibrosis","first-page":"433","article-title":"Clinical trials in IPF: what are the best endpoints?","author":"Spagnolo","year":"2019"},{"key":"10.1016\/j.lfs.2022.121048_bb0330","series-title":"Effectiveness of Combined Therapy With Pirfenidone and Inhaled N-acetylcysteine for Advanced Idiopathic Pulmonary Fibrosis: A Case\u2013control Study","first-page":"445","volume":"20","author":"Sakamoto","year":"2015"},{"key":"10.1016\/j.lfs.2022.121048_bb0335","first-page":"S195","article-title":"Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape","volume":"25","author":"Glassberg","year":"2019","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.lfs.2022.121048_bb0340","first-page":"1","article-title":"Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis","volume":"10","author":"Kang","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2022.121048_bb0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-019-0977-2","article-title":"Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the czech EMPIRE registry","volume":"20","author":"Zurkova","year":"2019","journal-title":"Respir. Res."},{"key":"10.1016\/j.lfs.2022.121048_bb0350","series-title":"The Effectiveness, Safety, and Tolerability of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Retrospective Study","first-page":"1126","volume":"36","author":"Hanta","year":"2019"},{"key":"10.1016\/j.lfs.2022.121048_bb0355","series-title":"The Use of Validated and Nonvalidated Surrogate Endpoints in Two European Medicines Agency Expedited Approval Pathways: A Cross-sectional Study of Products Authorised 2011\u20132018","volume":"16","author":"Schuster Bruce","year":"2019"},{"key":"10.1016\/j.lfs.2022.121048_bb0360","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.rmed.2019.04.016","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment","volume":"153","author":"Nathan","year":"2019","journal-title":"Respir. Med."},{"key":"10.1016\/j.lfs.2022.121048_bb0365","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1667\/RR15017.1","article-title":"Antifibrotic agent pirfenidone protects against development of radiation-induced pulmonary fibrosis in a murine model","volume":"190","author":"Qin","year":"2018","journal-title":"Radiat. Res."},{"key":"10.1016\/j.lfs.2022.121048_bb0370","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.rmed.2019.08.006","article-title":"Pirfenidone in real life: a retrospective observational multicentre study in italian patients with idiopathic pulmonary fibrosis","volume":"156","author":"Vancheri","year":"2019","journal-title":"Respir. Med."},{"key":"10.1016\/j.lfs.2022.121048_bb0375","series-title":"Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis","first-page":"756","volume":"196","author":"Ley","year":"2017"},{"key":"10.1016\/j.lfs.2022.121048_bb0380","series-title":"Novel Approaches in Cardiac Imaging for Non-invasive Assessment of Left Heart Myocardial Fibrosis","first-page":"292","volume":"8","author":"Mandoli","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0385","series-title":"Pirfenidone is a Cardioprotective Drug: Mechanisms of Action and Preclinical Evidence","volume":"155","author":"Aimo","year":"2020"},{"key":"10.1016\/j.lfs.2022.121048_bb0390","series-title":"Tartrate-resistant Acid Phosphatase 5 Promotes Pulmonary Fibrosis by Modulating \u03b2-catenin Signaling","first-page":"1","volume":"13","author":"Hu","year":"2022"},{"key":"10.1016\/j.lfs.2022.121048_bb0395","series-title":"Pirfenidone in Heart Failure With Preserved Ejection Fraction\u2014Rationale and Design of the PIROUETTE Trial","first-page":"461","volume":"33","author":"Lewis","year":"2019"},{"key":"10.1016\/j.lfs.2022.121048_bb0400","series-title":"Pirfenidone and Vitamin D Mitigate Renal Fibrosis Induced by Doxorubicin in Mice With Ehrlich Solid Tumor","volume":"288","author":"Hazem","year":"2022"},{"key":"10.1016\/j.lfs.2022.121048_bb0405","series-title":"Inflammation and Fibrosis in Murine Models of Heart Failure","first-page":"1","volume":"114","author":"Bacmeister","year":"2019"},{"key":"10.1016\/j.lfs.2022.121048_bb0410","series-title":"Cardiac Fibrosis: Potential Therapeutic Targets","first-page":"121","volume":"209","author":"Park","year":"2019"},{"key":"10.1016\/j.lfs.2022.121048_bb0415","series-title":"Pirfenidone in Heart Failure With Preserved Ejection Fraction: A Randomized Phase 2 Trial","first-page":"1477","volume":"27","author":"Lewis","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0420","series-title":"Pirfenidone as a Novel Cardiac Protective Treatment","first-page":"1","author":"Aimo","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0425","series-title":"Transforming Growth Factor \u03b2 (TGF\u03b2) and Related Molecules in Chronic Kidney Disease (CKD)","first-page":"287","volume":"133","author":"Huynh","year":"2019"},{"key":"10.1016\/j.lfs.2022.121048_bb0430","series-title":"Crosstalk Between Lipids and Mitochondria in Diabetic Kidney Disease","first-page":"1","volume":"19","author":"Ducasa","year":"2019"},{"key":"10.1016\/j.lfs.2022.121048_bb0435","series-title":"Microvesicles Containing miR-34a Induce Apoptosis of Proximal Tubular Epithelial Cells and Participate in Renal Interstitial Fibrosis","first-page":"2310","volume":"17","author":"Li","year":"2019"},{"key":"10.1016\/j.lfs.2022.121048_bb0440","series-title":"Quercetin Alleviates Kidney Fibrosis by Reducing Renal Tubular Epithelial Cell Senescence Through the SIRT1\/PINK1\/mitophagy Axis","first-page":"118116","volume":"257","author":"Liu","year":"2020"},{"key":"10.1016\/j.lfs.2022.121048_bb0445","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1152\/physiolgenomics.00039.2017","article-title":"Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD","volume":"50","author":"Lv","year":"2018","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.lfs.2022.121048_bb0450","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mam.2018.07.001","article-title":"Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities","volume":"65","author":"Frangogiannis","year":"2019","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.lfs.2022.121048_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174503","article-title":"Pirfenidone is a renal protective drug: mechanisms, signalling pathways, and preclinical evidence","volume":"911","author":"Bai","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2022.121048_bb0460","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.603802","article-title":"Metformin attenuates renal fibrosis in a mouse model of adenine-induced renal injury through inhibiting TGF-\u03b21 signaling pathways","volume":"9","author":"Yi","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.lfs.2022.121048_bb0465","first-page":"06","article-title":"A brief review on pleiotropic effects of pirfenidone-novel and ongoing outcomes","volume":"8","author":"Ravishankar","year":"2019","journal-title":"Int. J. Res. Dev. Pharm. Life Sci."},{"key":"10.1016\/j.lfs.2022.121048_bb0470","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021787","article-title":"Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"8","author":"Jiang","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.lfs.2022.121048_bb0475","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fphar.2017.00461","article-title":"Targeting TGF-\u03b2 mediated SMAD signaling for the prevention of fibrosis","volume":"8","author":"Walton","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2022.121048_bb0480","series-title":"Ameliorative Effect of Marine Macro-algae Against Carbon Tetrachloride (CCl4) Induced Hepatic Fibrosis and Associated Complications in Rats","author":"Azam","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12906-018-2406-3","article-title":"Probiotics and yogurt modulate oxidative stress and fibrosis in livers of Schistosoma mansoni-infected mice","volume":"19","author":"El-Khadragy","year":"2019","journal-title":"BMC Complement. Altern. Med."},{"key":"10.1016\/j.lfs.2022.121048_bb0490","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3389\/fphar.2017.00514","article-title":"Effects of enzymatically depolymerized low molecular weight heparins on CCl4-induced liver fibrosis","volume":"8","author":"Yan","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2022.121048_bb0495","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.2147\/DDDT.S194787","article-title":"Salvianolic acid a attenuates CCl4-induced liver fibrosis by regulating the PI3K\/AKT\/mTOR, Bcl-2\/Bax and caspase-3\/cleaved caspase-3 signaling pathways","volume":"13","author":"Wang","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.lfs.2022.121048_bb0500","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jhep.2020.04.011","article-title":"Animal models for liver disease\u2013A practical approach for translational research","volume":"73","author":"Nevzorova","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.lfs.2022.121048_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100745","article-title":"Choosing the right animal model for renal cancer research","volume":"13","author":"Sobczuk","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.lfs.2022.121048_bb0510","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.intimp.2018.09.021","article-title":"Lisinopril inhibits nuclear transcription factor kappa B and augments sensitivity to silymarin in experimental liver fibrosis","volume":"64","author":"Saber","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.lfs.2022.121048_bb0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204336","article-title":"Dexamethasone counteracts hepatic inflammation and oxidative stress in cholestatic rats via CAR activation","volume":"13","author":"Gabbia","year":"2018","journal-title":"PloS one"},{"key":"10.1016\/j.lfs.2022.121048_bb0520","series-title":"The Anti-fibrotic Drug Pirfenidone Inhibits Liver Fibrosis by Targeting the Small Oxidoreductase Glutaredoxin-1","volume":"7","author":"Xi","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0525","article-title":"Role of pirfenidone in TGF-\u03b2 pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective","volume":"1\u201316","author":"Hamidi","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.lfs.2022.121048_bb0530","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1165\/rcmb.2015-0020TR","article-title":"Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis","volume":"53","author":"Craig","year":"2015","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.lfs.2022.121048_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104694","article-title":"Pirfenidone is a cardioprotective drug: mechanisms of action and preclinical evidence","volume":"155","author":"Aimo","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2022.121048_bb0540","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1089\/wound.2019.1032","article-title":"The role of the anti-inflammatory cytokine interleukin-10 in tissue fibrosis","volume":"9","author":"Steen","year":"2020","journal-title":"Adv. Wound Care"},{"key":"10.1016\/j.lfs.2022.121048_bb0545","first-page":"2626","article-title":"Pirfenidone inhibits migration, differentiation, and proliferation of human retinal pigment epithelial cells in vitro","volume":"19","author":"Wang","year":"2013","journal-title":"Mol. Vis."},{"key":"10.1016\/j.lfs.2022.121048_bb0550","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/22221751.2020.1747363","article-title":"Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients","volume":"9","author":"Xiong","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.lfs.2022.121048_bb0555","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/281613","article-title":"Fas\/FasL pathway participates in regulation of antiviral and inflammatory response during mousepox infection of lungs","volume":"2015","author":"Bie\u0144","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.lfs.2022.121048_bb0560","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.pharep.2019.04.005","article-title":"Protective role of pirfenidone against experimentally-induced pancreatitis","volume":"71","author":"El-Kashef","year":"2019","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.lfs.2022.121048_bb0565","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.molimm.2018.05.003","article-title":"Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation","volume":"99","author":"Li","year":"2018","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.lfs.2022.121048_bb0570","series-title":"Pirfenidone Attenuates Homocysteine-induced Apoptosis by Regulating the Connexin 43 Pathway in H9C2 Cells","first-page":"1081","volume":"45","author":"Chen","year":"2020"},{"key":"10.1016\/j.lfs.2022.121048_bb0575","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.sajb.2022.06.051","article-title":"Potential topoisomerases inhibitors from asergillus terreus using virtual screening","volume":"149","author":"Attia","year":"2022","journal-title":"S. Afr. J. Bot."},{"key":"10.1016\/j.lfs.2022.121048_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105770","article-title":"Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2","volume":"123","author":"El-Naggar","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.lfs.2022.121048_bb0585","article-title":"Design and synthesis of novel benzoazoninone derivatives as potential CBSIs and apoptotic inducers: in Vitro, in Vivo, molecular docking, molecular dynamics, and SAR studies","volume":"127","author":"Hammouda","year":"2022","journal-title":"Bioinorg. Chem."},{"key":"10.1016\/j.lfs.2022.121048_bb0590","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1080\/13880209.2022.2098346","article-title":"Cytotoxic effects of extracts obtained from plants of the Oleaceae family: bio-guided isolation and molecular docking of new secoiridoids from Jasminum humile","volume":"60","author":"Mansour","year":"2022","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.lfs.2022.121048_bb0595","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1021\/acsomega.1c05519","article-title":"In silico and in vitro studies for benzimidazole anthelmintics repurposing as VEGFR-2 antagonists: novel mebendazole-loaded mixed micelles with enhanced dissolution and anticancer activity","volume":"7","author":"Elmaaty","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.lfs.2022.121048_bb0600","doi-asserted-by":"crossref","first-page":"9975","DOI":"10.1039\/D2NJ00050D","article-title":"Quinoxaline derivatives as a promising scaffold for breast cancer treatment","volume":"46","author":"Ezz Eldin","year":"2022","journal-title":"New J. Chem."},{"key":"10.1016\/j.lfs.2022.121048_bb0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2022.2082533","article-title":"Synthesis, structural characterization, DFT calculations, molecular docking, and molecular dynamics simulations of a novel ferrocene derivative to unravel its potential antitumor activity","author":"Hammoud","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.lfs.2022.121048_bb0610","doi-asserted-by":"crossref","first-page":"11422","DOI":"10.1039\/D2NJ01646J","article-title":"Design, synthesis, biological evaluation, and SAR studies of novel cyclopentaquinoline derivatives as DNA intercalators, topoisomerase II inhibitors, and apoptotic inducers","volume":"46","author":"Hammoud","year":"2022","journal-title":"New J. Chem."},{"key":"10.1016\/j.lfs.2022.121048_bb0615","first-page":"9","article-title":"Design and synthesis of new quinoxaline derivatives as potential histone deacetylase inhibitors targeting hepatocellular carcinoma: in silico, in vitro, and SAR studies","author":"Ma","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.lfs.2022.121048_bb0620","doi-asserted-by":"crossref","first-page":"24506","DOI":"10.18632\/oncotarget.15534","article-title":"Pirfenidone normalizes the tumor microenvironment to improve chemotherapy","volume":"8","author":"Polydorou","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2022.121048_bb0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-67904-8","article-title":"Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer","volume":"10","author":"Fujiwara","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2022.121048_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2019.101880","article-title":"Lung cancer in patients with idiopathic pulmonary fibrosis. A retrospective multicenter study in Greece","volume":"60","author":"Tzouvelekis","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2022.121048_bb0635","article-title":"Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice","volume":"9","author":"Qin","year":"2020"},{"key":"10.1016\/j.lfs.2022.121048_bb0640","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/intbio\/zyaa014","article-title":"Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta","volume":"12","author":"Aboulkheyr Es","year":"2020","journal-title":"Integr. Biol."},{"key":"10.1016\/j.lfs.2022.121048_bb0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0356-4","article-title":"Targeting the TGF\u03b2 pathway with galunisertib, a TGF\u03b2RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade","volume":"6","author":"Holmgaard","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lfs.2022.121048_bb0650","doi-asserted-by":"crossref","first-page":"14941","DOI":"10.1002\/jcp.28333","article-title":"Is it true that gut microbiota is considered as panacea in cancer therapy?","volume":"234","author":"Salek Farrokhi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.lfs.2022.121048_bb0655","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2162-z","article-title":"The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts","volume":"16","author":"Mediavilla-Varela","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lfs.2022.121048_bb0660","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1080\/14756366.2022.2105322","article-title":"Ligand-based design, synthesis, computational insights, and in vitro studies of novel N-(5-Nitrothiazol-2-yl)-carboxamido derivatives as potent inhibitors of SARS-CoV-2 main protease","volume":"37","author":"Elagawany","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.lfs.2022.121048_bb0665","doi-asserted-by":"crossref","first-page":"12920","DOI":"10.1038\/s41598-022-17082-6","article-title":"Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies","volume":"12","author":"Kutkat","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2022.121048_bb0670","doi-asserted-by":"crossref","DOI":"10.4081\/monaldi.2020.1298","article-title":"COVID-19: a review","volume":"90","author":"Madabhavi","year":"2020","journal-title":"Monaldi Arch. Chest Dis."},{"key":"10.1016\/j.lfs.2022.121048_bb0675","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3390\/pathogens11080834","article-title":"Insight into genetic characteristics of identified SARS-CoV-2 variants in Egypt from march 2020 to may 2021","volume":"11","author":"Roshdy","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.lfs.2022.121048_bb0680","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2147\/DDDT.S354841","article-title":"A systematic review of the global intervention for SARS-CoV-2 combating: from drugs repurposing to molnupiravir approval","volume":"16","author":"Ashour","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.lfs.2022.121048_bb0685","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1039\/D1NJ04816C","article-title":"Newly synthesized series of oxoindole\u2013oxadiazole conjugates as potential anti-SARS-CoV-2 agents: in silico and in vitro studies","volume":"46","author":"El-Masry","year":"2022","journal-title":"New J. Chem."},{"key":"10.1016\/j.lfs.2022.121048_bb0690","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3389\/fimmu.2020.01446","article-title":"The COVID-19 cytokine storm; what we know so far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2022.121048_bb0695","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.3390\/molecules26216559","article-title":"Naturally available flavonoid aglycones as potential antiviral drug candidates against SARS-CoV-2","volume":"26","author":"Al-Karmalawy","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2022.121048_bb0700","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3390\/vaccines9111317","article-title":"Coronavirus disease (COVID-19) control between drug repurposing and vaccination: a comprehensive overview","volume":"9","author":"Al-Karmalawy","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.lfs.2022.121048_bb0705","first-page":"20","article-title":"Examining Malaysian public letters to editor on Covid-19 pandemic: a corpus-assisted discourse analysis","author":"Joharry","year":"2020","journal-title":"GEMA Online\u00ae J. Lang. Stud."},{"key":"10.1016\/j.lfs.2022.121048_bb0710","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(20)30627-9","article-title":"COVID-19 and Italy: what next?","volume":"395","author":"Remuzzi","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2022.121048_bb0715","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.3390\/jcm9061917","article-title":"COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection","volume":"9","author":"Lechowicz","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lfs.2022.121048_bb0720","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S2213-2600(20)30225-3","article-title":"Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lfs.2022.121048_bb0725","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.3390\/molecules26195844","article-title":"Pimenta dioica (L.) Merr. Bioactive constituents exert anti-SARS-CoV-2 and anti-inflammatory activities: molecular docking and dynamics, in vitro, and in vivo studies","volume":"26","author":"El Gizawy","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2022.121048_bb0730","doi-asserted-by":"crossref","first-page":"35536","DOI":"10.1039\/D1RA04820A","article-title":"\u03b2-blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 mpro inhibitors: rational based design, in silico, in vitro, and SAR studies for lead optimization","volume":"11","author":"Hamed","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.lfs.2022.121048_bb0735","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.3390\/molecules26206182","article-title":"In silico and in vivo evaluation of SARS-CoV-2 predicted epitopes-based candidate vaccine","volume":"26","author":"Shehata","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2022.121048_bb0740","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.3390\/molecules26123772","article-title":"Computational insights on the potential of some NSAIDs for treating COVID-19: priority set and lead optimization","volume":"26","author":"Abo Elmaaty","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2022.121048_bb0745","doi-asserted-by":"crossref","first-page":"31339","DOI":"10.1039\/D1RA05817G","article-title":"Investigating the structure\u2013activity relationship of marine natural polyketides as promising SARS-CoV-2 main protease inhibitors","volume":"11","author":"El-Demerdash","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.lfs.2022.121048_bb0750","doi-asserted-by":"crossref","first-page":"29267","DOI":"10.1039\/D1RA05268C","article-title":"Anti-SARS-CoV-2 activities of tanshinone IIA, carnosic acid, rosmarinic acid, salvianolic acid, baicalein, and glycyrrhetinic acid between computational and in vitro insights","volume":"11","author":"Elebeedy","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.lfs.2022.121048_bb0755","doi-asserted-by":"crossref","first-page":"10027","DOI":"10.1039\/D0RA10674G","article-title":"Revisiting activity of some glucocorticoids as a potential inhibitor of SARS-CoV-2 main protease: theoretical study","volume":"11","author":"Elmaaty","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.lfs.2022.121048_bb0760","series-title":"Combined Pirfenidone, Azithromycin and Prednisolone in Post-H1N1 ARDS Pulmonary Fibrosis","first-page":"85","volume":"35","author":"Saha","year":"2018"},{"key":"10.1016\/j.lfs.2022.121048_bb0765","series-title":"Post-inflammatory Pulmonary Fibrosis in a Discharged COVID-19 Patient: Effectively Treated With Pirfenidone","first-page":"051","volume":"6","author":"Xi","year":"2020"},{"key":"10.1016\/j.lfs.2022.121048_bb0770","series-title":"Pulmonary Fibrosis in Critical Ill Patients Recovered From COVID-19 Pneumonia: Preliminary Experience","first-page":"2134","volume":"38","author":"Fang","year":"2020"},{"key":"10.1016\/j.lfs.2022.121048_bb0775","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/jmv.26634","article-title":"Discharge may not be the end of treatment: pay attention to pulmonary fibrosis caused by severe COVID-19","volume":"93","author":"Zhang","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.lfs.2022.121048_bb0780","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00228-020-02947-4","article-title":"The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2","volume":"76","author":"Ferrara","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2022.121048_bb0785","article-title":"Pulmonary fibrosis after COVID-19 pneumonia","volume":"13","author":"Malik","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110005","article-title":"Pirfenidone: a novel hypothetical treatment for COVID-19","volume":"144","author":"Seifirad","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.lfs.2022.121048_bb0795","series-title":"A Refined Approach to Target the Molecular and Cellular Mechanisms in Pulmonary Fibrosis. Targeting Cellular Signalling Pathways in Lung Diseases","first-page":"311","author":"Singh","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0800","first-page":"7","article-title":"Effect of early initiation of combination therapy of anti-inflammatory and anti-fibrotic drugs on post COVID-19 interstitial lung disease: a case report","author":"Alsilmi","year":"2021","journal-title":"J. Contemp. Med. Sci."},{"key":"10.1016\/j.lfs.2022.121048_bb0805","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.ajem.2020.05.120","article-title":"Pulmonary fibrosis in critical ill patients recovered from COVID-19 pneumonia: preliminary experience","volume":"38","author":"Fang","year":"2020","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.lfs.2022.121048_bb0810","series-title":"A Study to Evaluate the Efficacy and Safety of Pirfenidone with Novel Coronavirus Infection","year":"2020"},{"key":"10.1016\/j.lfs.2022.121048_bb0815","series-title":"Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis With More Preserved Lung Function","first-page":"843","volume":"48","author":"Albera","year":"2016"},{"key":"10.1016\/j.lfs.2022.121048_bb0820","series-title":"Pharmacological Interactions of Nintedanib and Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic","first-page":"819","volume":"14","author":"Serra L\u00f3pez-Matencio","year":"2021"},{"key":"10.1016\/j.lfs.2022.121048_bb0825","series-title":"Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis","first-page":"9","author":"Zhou","year":"2022"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522007482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522007482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T17:51:13Z","timestamp":1735235473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320522007482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":165,"alternative-id":["S0024320522007482"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2022.121048","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and\/or anti-SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2022.121048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"121048"}}